Compare Biogen Inc (BIIB) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Oatly Group AB - ADR — how do they compare? Biogen Inc trades at $208.38 (market cap $30.13B), while Oatly Group AB - ADR trades at $13.24 (market cap $415.98M). The key difference: Biogen Inc is far larger — about 72.4× Oatly Group AB - ADR's market cap, and Biogen Inc is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals.
| BIIB | OTLY | |
|---|---|---|
Market Cap | $30.13B | $415.98M |
Sector | Health | Consumer Staples |
52-Week High | $216.63 | $18.54 |
52-Week Low | $128.93 | $8.03 |
Enterprise Value | $37.20B | $920.39M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
OTLY trades at $13.18, up 0.46% on the day, with a bullish technical signal driven by moving averages and oversold RSI conditions. Revenue growth is accelerating, with Q2 2026 sales reaching $240.1 million and full-year guidance raised, though the company remains unprofitable with a net margin of -13.81%. Cash flow trends show reduced operational losses, but negative free cash flow persists.
The outlook hinges on OTLY's path to profitability; improved gross margins and cost controls offer potential upside, but high debt and sustained cash burn pose significant risks. Analyst sentiment is mixed with a 44.44% buy rating, reflecting optimism for growth against financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
